News - Shire, Research


Current filters:


Popular Filters

arGEN-X and Shire sign long term collaboration deal worth $20 million

arGEN-X and Shire sign long term collaboration deal worth $20 million


Belgium-based preclinical stage biotech firm arGEN-X has entered into a long-term strategic alliance…

arGEN-XBiotechnologyBusiness FinanceEuropeHuman antibody discovery technologiesResearchShireShire Pharmaceuticals

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints


Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III


Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…


arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease

Shire reports mixed results from Phase III study of lifitegrast in dry eye disease


Ireland-headquartered drugmaker Shire (LSE: SHP) has announced mixed results from a Phase III efficacy…


Shire demonstrates efficacy of ADHD drug for binge eating


Shire has announced top-line results from two identically designed randomized placebo-controlled Phase…

EuropePharmaceuticalRare diseasesResearchShireVyvanse

Shire and Santaris extend strategic alliance


Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Shire's Elvanse shows significantly faster response in ADHD symptoms than Strattera


Ireland-headquartered Shire (LSE: SHP, NASDAQ: SHPG) presented positive scientific data comparing the…

Eli LillyElvanseNeurologicalPharmaceuticalResearchShireStrattera

Acceleron and Shire not to restart ACE-031 program


Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study


Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Ethris enters SNIM modified RNA alliance with Shire


German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Shire links with Boston Children's Hospital for pediatric rare disease research


Ireland-headquartered Shire (LSE: SHP) has entered into a three-year, broad research collaboration in…

PharmaceuticalRare diseasesResearchShire

Shire links with Italian foundation for research on rare diseases


Shire (LSE: SHP) has announced a long-term, broad based, multi-indication research collaboration in rare…

PharmaceuticalRare diseasesResearchShire

Shire's Vpriv shows significant improvement in Gaucher-related bone disease


Shire's Vpriv shows significant improvement in Gaucher-related bone disease

PharmaceuticalRare diseasesResearchShireVpriv

Efficacy of Shire's Vyvanse maintained in ADHD adolescents after at least six months


A significantly lower proportion of subjects experiencing treatment failure whilst receiving UK specialty…


Shire takes hit as bowel disease drug Lialda fails in Ph III trial


The shares of Ireland-headquartered Shire (LSE: SHP) dropped 4.9% to £20.14 in mid afternoon trading…


Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv


Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Shire drops Dermagraft for venous leg ulcers, after Ph III failure


Ireland-headquartered drugmaker Shire (LSE: SHP) says that Advanced BioHealing (ABH), the USA-based regenerative…

Advanced BioHealingBiotechnologyDermagraftDermatologicalsPharmaceuticalRegulationResearchShire

Back to top